CELLASTRA INC

PROGRAMMING THE HEALING  WOUND FOR NATURAL SCAR PREVENTION

 

 POWERING THE FUTURE OF AESTHETIC SURGERY AND BURN CARE

CELLASTRA NEWS

CELLASTRA GENE THERAPY REPORT OCTOBER 10,  2020

 ________________________READ MORE

CELLASTRA INC. 08/07/2020

Cellastra announces the appointment of  BIOTECanada veteran Brad Thompson, PhD, as Chairman of the Board and Ex Novartis veteran Vinod Kumar, MD, as Chief Medical Officer.  

                                          READ MORE

 

CELLASTRA INC 03/03/2020

Cellastra announces long-term results from in-vivo transgene expression of proprietary anti-scarring peptide

PrSan Francisco, CA, March 3, 2020  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has obtained promising results  for CELLEXA, a proprietary gene vector enabling in-vivo production of a potent anti-scarring peptide.

Cellastra recently reported results demonstrating that CELLEXA delivers the genetic code for the lactoferrin sub-peptide with the same amino acid sequence enabling expression during the first month of ovservation.

 “Our new results from long-term follow up demonstrates continued robust and durable transgenic expression and production of the peptide throughout the 11 week observation period  after intramuscular injection, and furthermore no adverse effects were noted” said Dr Karl Mettinger, MD, PhD, President & CEO of C

                                          READ MORE

02/19/2020

NEW GENE THERAPY INSTITUTE CREATE BY NIH

                                          READ MORE

INVESTOR PRESENTATION MARCH 2020

388 Market St #1300, San Francisco, CA 94111, USA

©2018 by Cellastra Inc. Proudly created with Wix.com